To carry out an exploratory evaluation of liver triglyceride content in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) using proton magnetic resonance spectroscopy and to study how both the treatment itself and the biochemical and physiological variables in which the treatment causes alterations are related to liver fat content.
Methods
Intracellular hepatic triglyceride content was determined in 29 HIV-1-infected patients on their first HAART regime by means of localized water-unsuppressed single voxel proton spectra. Other measurements were body mass index, waist-to-hip ratio, lipodystrophy assessment and a detailed blood biochemical analysis. The relationship between intracellular hepatic triglycerides and relevant descriptive, treatment and biochemical variables was studied by correlation and regression analysis.
Results
Intrahepatic triglycerides were detected in 58.6% of the patients and 13.8% showed a triglyceride content compatible with liver steatosis. Many variables (body mass index, waist-to-hip ratio, cumulative exposure to PIs, lactate, insulin, insulin resistance measured by the homeostasis model assessment method [HOMA-R index], pH, total triglycerides, high density lipoprotein cholesterol and very low density lipoprotein [VLDL] cholesterol) correlated individually with the amount of triglycerides. Stepwise multiple regression analysis showed that the combination of insulin or HOMA-R index and VLDL cholesterol accounted for up to 50.2% of the triglyceride liver variance. A positive relationship was found between the concomitant presence of the metabolic syndrome components (insulin resistance, dyslipidaemia and central obesity) and intrahepatic triglyceride content.
Conclusions
The study showed that intrahepatic triglyceride deposit appears to be a frequent feature of HIV-1-infected patients receiving HAART. A coherent multifactorial combination of biochemical and physiological factors associated with the deposit suggested that cumulative exposure to PIs might be a possible trigger event.
References
1.
CarrA.Toxicity of antiretroviral therapy and implications for drug development.Nat Rev Drug Discov2003; 2: 624–634.
2.
MontessoriV., PressN., HarrisM., AkagiL., MontanerJ.S.Adverse effects of antiretroviral therapy for HIV infection.Can Med Assoc J2004; 170: 229–238.
3.
ReavenG.M.Banting lecture 1988. Role of insulin resistance in human disease.Diabetes1988; 37: 1595–1607.
4.
GazzarusoC., SacchiP., GarzanitiA., FratinoP., BrunoR., FiliceG.Prevalence of metabolic syndrome among HIV patients.Diabetes Care2002; 25: 1253–1254.
5.
IsomaaB., AlmgrenP., TuomiT.Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diabetes Care2001; 24: 683–689.
6.
HaffnerS.M., ValdezR.A., HazudaH.P., MitchellB.D., MoralesP.A., SternM.P.Prospective analysis of the insulin-resistance syndrome (syndrome X).Diabetes1992; 41: 715–722.
7.
LonerganJ., BehlingC., PfanderH., HassaneinT., MathewsS.Hyperlactatemia and hepatic abnormalities in 10 HIV infected patients receiving nucleoside analogue combination regimens.Clin Infect Dis2000; 31: 162–166.
8.
SutinenJ., HakkinenA.M., WesterbackaJ.Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy.AIDS2002; 16: 2183–2193.
9.
RuhlC.E., EverhartJ.E.Epidemiology of nonalcoholic fatty liver.Clin Liver Dis2004; 8: 501–519.
10.
LongoR., RicciC., MasuttiF.Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography.Invest Radiol1993; 28: 297–302.
11.
ThomsenC., BeckerU., WinklerK., ChristoffersenP., JensenM., HenriksenO.Quantification of liver fat using magnetic resonance spectroscopy.Magn Reson Imaging1994; 12: 487–495.
12.
SzczepaniakL.S., BabcockE.E., SchickF.Measurement of intracellular triglyceride stores by 1H spectroscopy: validation in vivo.Am J Physiol1999; 276: E977–E989.
13.
SzczepaniakL.S., NurenbergP., LeonardD.Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.Am J Physiol Endocrinol Metab2005; 288: E462–E468.
SchonfeldG., PattersonB.W., YablonskiyD.A.Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis.J Lipid Res2003; 44: 470–478.
16.
den BoerM., VosholP.J., KuipersF., HavekesL.M., RomijnJ.A.Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.Arterioscler Thromb Vasc Biol2004; 24: 644–649.
17.
MarchesiniG., BriziM., Morselli-LabateA.M.Association of non-alcoholic fatty liver disease to insulin resistance.Am J Med1999; 107: 450–455.
18.
MarchesiniG., BriziM., BianchiG.Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.Diabetes2001; 50: 1844–1850.
19.
RyysyL., HakkinenA.M., GotoT.Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.Diabetes2000; 49: 749–758.
20.
LemieuxS., Prud'hommeD., BouchardC., TremblayA., DespresJ.P.A single threshold of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue.Am J Clin Nutr1996; 64: 685–693.
21.
ChristeffN., MelchiorJ.C., de TruchisP., PerronneC., NunezE.A., GougeonM.L.Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations.AIDS1999; 13: 2251–2260.
22.
MatthewsD.R., HoskerJ.P., RudenskiA.S., NaylorB.A., TreacherD.F., TurnerR.C.Homeostasis model assessment.Diabetologia1985; 28: 412–419.
23.
AscasoJ.F., RomeroP., RealJ.T., PriegoA., ValdecabresC., CarmenaR.Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population.Med Clin (Barc)2001; 117: 530–533.
24.
AscasoJ.F., RomeroP., RealJ.T., LorenteR.I., Martinez-VallsJ., CarmenaR.Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population.Eur J Intern Med2003; 14: 101–106.
25.
AlbertiK.G., ZimmetP.Z.Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation.Diabet Med1998; 15: 539–553.
26.
KorinH.W., EhmanR.L., RiedererS.J., FelmleeJ.P., GrimmR.C.Respiratory kinematics of the upper abdominal organs: a quantitative study.Magn Reson Med1992; 23: 172–178.
Moreno-TorresA., PujolJ., Soriano-MasC., DeusJ., IranzoA., SantamariaJ.Age-related metabolic changes in the upper brainstem tegmentum by MR spectroscopy.Neurobiol Aging2005; 26: 1051–1059.
29.
Katz-BrullR., RofskyN.M., LenkinskiR.E.Breathhold abdominal and thoracic proton MR spectroscopy at 3T.Magn Reson Med2003; 50: 461–467.
30.
Van der VeenJ.W., de BeerR., LuytenP.R., van OrmondtD.Accurate quantification of in vivo31P NMR signals using the variable projection method and prior knowledge.Magn Reson Med1988; 6: 92–98.
PirothL.Liver steatosis in HIV-infected patients.AIDS Rev2005; 7: 197–209.
33.
ParesA., TresserrasR., NunezI.Prevalence and factors associated to the presence of fatty liver in apparently healthy adult men.Med Clin (Barc)2000; 114: 561–565.
34.
ThomopoulosK.C., ArvanitiV., TsamantasA.C.Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis.Eur J Gastroenterol Hepatol2006; 18: 233–237.
35.
SulkowskiM.S., MehtaS.H., TorbensonM.Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus.AIDS2005; 19: 585–592.
36.
KralJ.G., SchaffnerF., PiersonR.N.Jr., WangJ.Body fat topography as an independent predictor of fatty liver.Metabolism1993; 42: 548–551.
37.
AnguloP., KeachJ.C., BattsK.P., LindorK.D.Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.Hepatology1999; 30: 1356–1362.
38.
MurphyD.J.The biogenesis and functions of lipid bodies in animals, plants and microorganisms.Prog Lipid Res2001; 40: 325–438.
39.
NolanD.Metabolic complications associated with HIV protease inhibitor therapy.Drugs2003; 63: 2555–2574.
40.
CarpentierA., PattersonB.W., UffelmanK.D., SalitI., LewisG.F.Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals.Atherosclerosis2005; 178: 165–172.
41.
RiddleT.M., KuhelD.G., WoollettL.A., FichtenbaumC.J., HuiD.Y.HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.J Biol Chem2001; 276: 37514–37519.
42.
SanyalA.J.Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.Nat Clin Pract Gastroenterol Hepatol2005; 2: 46–53.
43.
BrinkmanK.Editorial Response: Hyperlactatemia and Hepatic Steatosis as Features of Mitochondrial Toxicity of Nucleoside Analogue Reverse Transcriptase Inhibitors.Clin Infect Dis2000; 31: 167–169.
44.
BonoraE., TargherG., AlbericheM.Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.Diabetes Care2000; 23: 57–63.
45.
KahnR., BuseJ., FerranniniE., SternM.The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care2005; 28: 2289–2304.
46.
AlbertiK.G., ZimmetP., ShawJ.The metabolic syndrome -a new worldwide definition.Lancet2005; 366: 1059–1062.
